Standards, Harmonization and Cultural Differences: Examining the Implementation of a European Stem Cell Clinical Trial (2019)
Hauskeller, Christine (Author)
Baur, Nicole (Author)
Harrington, Jean (Author)
Science as Culture
Volume: 28
Issue: 2
Pages: 174-199
A complex set of European regulations aims to facilitate regenerative medicine, harmonizing good clinical and manufacturing standards and streamlining ethical approval procedures. The sociology of standardization has elaborated some of the effects of regulation but little is known about how such implementation works in practice across institutions and countries in regenerative medicine. The effects of transnational harmonization of clinical trial conduct are complex. A long-term ethnographic study alongside a multinational clinical trial finds a range of obstacles. Harmonization standardizes at one level, but implementing the standards brings to the fore new layers of difference between countries. Europe-wide harmonization of regulations currently disadvantages low-cost clinician-lead research in comparison to industry-sponsored clinical trials. Moreover, harmonized standards must be aligned with the cultural variations in everyday practice across European countries. Each clinical team must find its own way of bridging harmonized compulsory practice with how things are done where they are, respecting expectations from both patients and the local hospital ethics committee. Established ways of working must further be adapted to a range of institutional and cultural conventions that affect the clinical trial such as insurance practices and understandings of patient autonomy. An additional finding is that the specific practical roles of team members in the trial affect their evaluation of the importance of these challenges. Our findings lead to conclusions of wider significance for the sociology of standards concerning how regulation works and for medical sociology about how trial funding and research directions in stem cell medicine intersect.
...MoreArticle Achim Rosemann (2019) Alter-Standardizing Clinical Trials: The Gold Standard in the Crossfire. Science as Culture (pp. 125-148).
Similar Citations
Article
Stephens, Neil;
Atkinson, Paul;
Glasner, Peter;
(December 2011)
Documenting the doable and doing the documented: Bridging strategies at the UK Stem Cell Bank
(/isis/citation/CBB128580755/)
Article
Colleen Lanier-Christensen;
(September 2021)
Creating Regulatory Harmony: The Participatory Politics of OECD Chemical Testing Standards in the Making
(/isis/citation/CBB606231580/)
Article
Gail Davies;
(2021)
Locating the ‘culture wars’ in laboratory animal research: National constitutions and global competition
(/isis/citation/CBB369219796/)
Article
Achim Rosemann;
Federico Vasen;
Gabriela Bortz;
(2019)
Global Diversification in Medicine Regulation: Insights from Regenerative Stem Cell Medicine
(/isis/citation/CBB976475287/)
Article
Margaret Sleeboom-Faulkner;
(June 2019)
Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine
(/isis/citation/CBB470996355/)
Article
Sibille Merz;
(July 2021)
Global Trials, Local Bodies: Negotiating Difference and Sameness in Indian For-profit Clinical Trials
(/isis/citation/CBB863654493/)
Article
Catherine M. Montgomery;
(2017)
From Standardization to Adaptation: Clinical Trials and the Moral Economy of Anticipation
(/isis/citation/CBB888998669/)
Article
Achim Rosemann;
(2019)
Alter-Standardizing Clinical Trials: The Gold Standard in the Crossfire
(/isis/citation/CBB107905760/)
Article
Grace Ballor;
(Spring 2022)
CE Marking, Business, and European Market Integration
(/isis/citation/CBB954430091/)
Article
Petty, JuLeigh;
Heimer, Carol A.;
(2011)
Extending the rails: How research reshapes clinics
(/isis/citation/CBB060848255/)
Article
Achim Rosemann;
Nattaka Chaisinthop;
(2016)
The Pluralization of the International: Resistance and Alter-Standardization in Regenerative Stem Cell Medicine
(/isis/citation/CBB916364477/)
Book
Greene, Jeremy A.;
Watkins, Elizabeth Siegel;
(2012)
Prescribed: Writing, Filling, Using, and Abusing the Prescription in Modern America
(/isis/citation/CBB001214574/)
Chapter
Lorenzo Beltrame;
(2015)
Cellule e ordine sociale: il dibattito italiano sulle cellule staminali
(/isis/citation/CBB813029159/)
Article
Sonja Erikainen;
Anna Couturier;
Sarah Chan;
(2020)
Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era
(/isis/citation/CBB771315477/)
Article
Salla Sariola;
Roger Jeffery;
Amar Jesani;
Gerard Porter;
(2019)
How Civil Society Organisations Changed the Regulation of Clinical Trials in India
(/isis/citation/CBB527783392/)
Article
Michael Morrison;
(2019)
Making Cells Worthwhile: Calculations of Value in a European Consortium for Induced Pluripotent Stem Cell Banking
(/isis/citation/CBB267974341/)
Article
Arthur Daemmrich;
(2019)
Welcoming (Newbie) Scholars to the Field
(/isis/citation/CBB904595256/)
Article
Kohli-Laven, Nina;
Bourret, Pascale;
Keating, Peter;
Cambrosio, Alberto;
(2011)
Cancer Clinical Trials in the Era of Genomic Signatures: Biomedical Innovation, Clinical Utility, and Regulatory-Scientific Hybrids
(/isis/citation/CBB001034675/)
Article
Kristrún Gunnarsdóttir;
Kjetil Rommetveit;
(2017)
The Biometric Imaginary: (dis)trust in a Policy Vacuum
(/isis/citation/CBB939896615/)
Article
Andrey Vozyanov;
(June 2018)
Solution into problem: Ukrainian Marshrutka and Romanian maxi-taxi at the fall of planning paradigms after 1990
(/isis/citation/CBB504216233/)
Be the first to comment!